Published 12 hours ago

Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse? - Johnson & Johnson (NYSE:JNJ)

Summary by Benzinga

Johnson & Johnson (NYSE:JNJ) will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and $22.44 billion in revenues as the company reports before market hours. The stock is down 8.88% over the past year, up 2.79% YTD. Johnson & Johnson's Spravato Wins FDA Nod Ahead Of Earnings Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone treatment for adults…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center2Last Updated4 hours agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse? - Johnson & Johnson (NYSE:JNJ)

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics